--- title: "Aclaris Therap | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1.996 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285538634.md" datetime: "2026-05-07T11:18:16.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285538634.md) - [en](https://longbridge.com/en/news/285538634.md) - [zh-HK](https://longbridge.com/zh-HK/news/285538634.md) --- # Aclaris Therap | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1.996 M Revenue: As of FY2026 Q1, the actual value is USD 1.996 M, beating the estimate of USD 1.322 M. EPS: As of FY2026 Q1, the actual value is USD -0.15, beating the estimate of USD -0.1578. EBIT: As of FY2026 Q1, the actual value is USD -23.71 M. #### Net Loss Aclaris Therapeutics, Inc. reported a net loss of - $19,824 thousand for the first quarter of 2026, which is an increase from the net loss of - $15,085 thousand for the first quarter of 2025. #### Operational Metrics - **Loss from Operations**: The loss from operations was - $22,192 thousand for the first quarter of 2026, an increase from - $18,084 thousand for the prior year period. - **Research and Development (R&D) Expenses**: R&D expenses increased to $15,657 thousand for the first quarter of 2026 from $11,584 thousand for the prior year period, primarily due to expenses for ATI-052 clinical development and ATI-9494 manufacturing costs, partially offset by reduced ATI-2138 expenses. - **General and Administrative (G&A) Expenses**: G&A expenses rose to $6,743 thousand for the first quarter of 2026 from $6,139 thousand for the prior year period, mainly due to increased professional, legal, and personnel expenses. - **Cost of Revenue**: Cost of revenue was $395 thousand for the first quarter of 2026, down from $506 thousand for the first quarter of 2025. - **Licensing Costs**: Licensing costs were $1,393 thousand for the first quarter of 2026, up from $1,010 thousand for the first quarter of 2025. - **Revaluation of Contingent Consideration**: No revaluation of contingent consideration occurred in the first quarter of 2026, compared to $300 thousand in the first quarter of 2025. - **Total Costs and Expenses**: Total costs and expenses were $24,188 thousand for the first quarter of 2026, an increase from $19,539 thousand for the first quarter of 2025. - **Total Other Income**: Total other income decreased to $2,368 thousand for the first quarter of 2026 from $2,999 thousand for the first quarter of 2025. - **Stock-Based Compensation Expense**: Stock-based compensation expense was $3,198 thousand for the first quarter of 2026, compared to $3,535 thousand for the first quarter of 2025. #### Cash Flow - **Net Cash Used in Operating Activities**: Net cash used in operating activities was - $18,149 thousand for the first quarter of 2026, an increase from - $13,057 thousand for the first quarter of 2025. #### Liquidity and Capital Resources - **Cash, Cash Equivalents and Marketable Securities**: As of March 31, 2026, Aclaris Therapeutics, Inc. held $190,788 thousand in cash, cash equivalents, and marketable securities, an increase from $151,363 thousand as of December 31, 2025. - **Proceeds from Stock Sale**: In March 2026, the company sold 18.4 million shares of common stock, generating aggregate gross proceeds of $59.8 million. - **Total Assets**: Total assets were $198,720 thousand as of March 31, 2026, up from $160,460 thousand as of December 31, 2025. - **Total Current Liabilities**: Total current liabilities were $27,370 thousand as of March 31, 2026, a decrease from $28,645 thousand as of December 31, 2025. - **Total Liabilities**: Total liabilities were $55,071 thousand as of March 31, 2026, down from $57,378 thousand as of December 31, 2025. - **Total Stockholders’ Equity**: Total stockholders’ equity increased to $143,649 thousand as of March 31, 2026, from $103,082 thousand as of December 31, 2025. #### Outlook / Guidance Aclaris Therapeutics, Inc. expects its cash, cash equivalents, and marketable securities to fund operations through the end of 2028. The company anticipates reporting top-line results from its Phase 1b trials of ATI-052 in asthma and atopic dermatitis, and its Phase 2 trial of bosakitug, in the second half of 2026 and fourth quarter of 2026, respectively. Additionally, Aclaris Therapeutics, Inc. plans to initiate a Phase 2b program for ATI-052, a Phase 2b basket study for ATI-2138, and file an IND for ATI-9494, all in the second half or fourth quarter of 2026. ### Related Stocks - [ACRS.US](https://longbridge.com/en/quote/ACRS.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Acenta Group delays Q1 interim report release to May 29, 2026](https://longbridge.com/en/news/287031560.md) - [OceanPal Inc. Announces 2026 Annual General Meeting of Shareholders to be Held on June 16, 2026 | SVRN Stock News](https://longbridge.com/en/news/286308382.md) - [CEO Kimberly A. Fields Becomes ATI Board Chair | ATI Stock News](https://longbridge.com/en/news/286474966.md)